Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Corbus Pharmaceuticals Holdings, Inc. (CRBP : NSDQ)

• Company Description    Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Number of Employees: 28

• Price / Volume Information    Yesterday's Closing Price: $8.36 Daily Weekly Monthly 20 Day Moving Average: 205,790 shares Shares Outstanding: 12.24 (millions) Market Capitalization: $102.30 (millions) Beta: 3.05 52 Week High: $61.90 52 Week Low: $4.64 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -8.83% -12.25% 12 Week 38.64% 16.61% Year To Date -29.15% -33.65%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 500 River Ridge Drive - Norwood,MA 02062 USA ph: 617-963-0100 fax: 617-663-6085 smoran@corbuspharma.com http://www.corbuspharma.com

• General Corporate Information    Officers Yuval Cohen - Chief Executive Officer and Director Alan Holmer - Chairman of the Board Sean Moran - Chief Financial Officer Anne Altmeyer - Director Yong Ben - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 21833P301 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/05/25 Share - Related Items Shares Outstanding: 12.24 Most Recent Split Date: 2.00 (0.03:1) Beta: 3.05 Market Capitalization: $102.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.57 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.80 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -67.47% vs. Previous Quarter: -78.21% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -36.87 12/31/24 - -31.20 ROA 06/30/25 - - 03/31/25 - -32.87 12/31/24 - -26.91 Current Ratio 06/30/25 - - 03/31/25 - 11.82 12/31/24 - 12.94 Quick Ratio 06/30/25 - - 03/31/25 - 11.82 12/31/24 - 12.94 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 10.39 12/31/24 - 11.69 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©